Fundraising Fox
BioStem Technologies
OTC: BSEMPompano Beach, US · Florida corporation
Find your way into BioStem Technologies
Sign up to see every warm intro you have to BioStem Technologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BioStem Technologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BioStem Technologies develops human amniotic membrane allograft products for advanced surgical care and wound care, used as adjunct treatments for chronic and acute wounds. Its offerings use cryopreserved, hydrated, and dehydrated membrane technologies for clinical and veteran patient populations.
Founders & leadership
AV
Andrew Van VurstExecutive
KG
Katherine GorrellChief Legal & Compliance OfficerKatherine Gorrell is an executive with legal and regulatory expertise in healthcare and life sciences, having advised organizations on compliance, governance, and operational strategy across Fortune 500, private equity, and nonprofit sectors.
BH
Barry HassettChief Commercial OfficerBarry Hassett has spent over 25 years in the medical device and biotechnology sector, with experience in sales, marketing, and leadership roles for implantable devices, biologics, and capital equipment across both large organizations and entrepreneurial ventures.
JM
Jason MatuszewskiCo-FounderJason Matuszewski is an executive officer and director at BioStem Technologies, where he leads operations for the development of amniotic membrane allograft products. He brings experience in advanced biologics manufacturing, regulatory compliance, and business development for biotechnology ventures.
Board
RL
Rayna Lesser HannawayBoard director
KW
Kenneth WarringtonBoard director
JU
Jodi UngrodtBoard director
TJ
Thomas J. DuganBoard director
PD
Patrick DalyBoard director
MG
Mark GlickmanBoard director
SS
Steven SonenreichBoard director
Reported raises · per SEC filings
Form D private placements$5.7M disclosed across 4 of 7 rounds · 2016–2026
▶$3MraisedOct 2026 · 2 investors · BiotechnologyRule 506(b)
▶$3MraisedOct 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason MatuszewskiExecutive Officer, Director
- Brandon PoeExecutive Officer
- Andrew Van VurstExecutive Officer, Director
- Barry HassettExecutive Officer
- Katherine GorrellExecutive Officer
- Kenneth WarringtonDirector
- Mark GlickmanDirector
- Rayna Lesser HannawayDirector
- Jodi UngrodtDirector
- Steven SonenreichDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Sep 2026
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$40MofferedSep 2026 · 1 investors · BiotechnologyRule 506(b)
▶$40MofferedSep 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason MatuszewskiExecutive Officer, Director
- Brandon PoeExecutive Officer
- Andrew Van VurstExecutive Officer, Director
- Barry HassettExecutive Officer
- Katherine GorrellExecutive Officer
- Kenneth WarringtonDirector
- Mark GlickmanDirector
- Rayna Lesser HannawayDirector
- Jodi UngrodtDirector
- Steven SonenreichDirector
- Offering amount
- $40M
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$2.5MraisedJun 2026 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJun 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew Van VurstExecutive Officer, Director
- Brandon PoeExecutive Officer
- Kenneth WarringtonDirector
- Jodi UngrodtDirector
- Katherine GorrellExecutive Officer
- Thomas J. DuganDirector
- Patrick DalyDirector
- Barry HassettExecutive Officer
- Jason MatuszewskiExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- May 2026
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$220KraisedApr 2023 · 5 investors · BiotechnologyRule 506(c)
▶$220KraisedApr 2023 · 5 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Andrew Smith-Van VurstExecutive Officer, Director
- Jason MatuszewskiExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $220K
- First sale
- Mar 2023
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06c
▶$3MofferedMay 2021 · BiotechnologyRule 506(b)
▶$3MofferedMay 2021 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason MatuszewskiExecutive Officer, Director
- Andrew Smith-Van VurstExecutive Officer, Director
- Offering amount
- $3M
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$10KraisedAug 2016 · 1 investors · BiotechnologyRule 506(c)
▶$10KraisedAug 2016 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Jason MatuszewskiExecutive Officer, Director
- Robert WatsonDirector
- Andrew VanVurstExecutive Officer, Director
- Henry VanVurstExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $10K
- First sale
- Aug 2016
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06c
▶$6MofferedFeb 2016 · BiotechnologyRule 506(b)
▶$6MofferedFeb 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason Victor MatuszewskiExecutive Officer
- Offering amount
- $6M
- Minimum investment
- $5K
- Proceeds to insiders
- $185K
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as BioStem Technologies.
In the news
BioStem Technologies Reports Second Quarter 2026 Financial Results - BioSpacebiospace.com · Aug 2026
BioStem Technologies Q2 Revenue Rises 29%prismmediawire.com · Aug 2026BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission - BioSpacebiospace.com · Jul 2026BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies - BioSpacebiospace.com · Jul 2026BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor - BioSpacebiospace.com · May 2026Frequently asked questions
- What does BioStem Technologies do?
- BioStem Technologies develops human amniotic membrane allograft products for advanced surgical care and wound care, used as adjunct treatments for chronic and acute wounds. Its offerings use cryopreserved, hydrated, and dehydrated membrane technologies for clinical and veteran patient populations.
- How much funding has BioStem Technologies raised?
- BioStem Technologies has disclosed $5.7M raised across 4 of its 7 known rounds.
- Where is BioStem Technologies headquartered?
- BioStem Technologies is headquartered in Pompano Beach, US.